ERCC2 and ovarian cancer: Heterozygous ERCC2 Asp312Asn with BMI > 25 exhibited a significant increase in ovarian cancer risk (OR = 3.5; 95% CI = 1.00–12.26), while heterozygous ERCC2 Lys751Gln with body mass index (BMI) < 25 exhibited an upward tendency in ovarian cancer risk (OR = 5.64; 95% CI = 0.93–33.99).